This content was accurate at the time of release, 26 December 2021. Accreditation for this course expired on 27 December 2022. If you would still like an activity completion certificate, send your request to firstname.lastname@example.org.
This case study features expert discussion surrounding a real HCM patient and is designed to raise awareness for the importance of regularly screening family members for HCM and provide you with an understanding of the HCM screening types. It assists clinicians in community practice or those with an interest in HCM management to:
- recognize the importance of genetic testing / counseling for HCM, along with the limitations
- understand when the different types of HCM screening might be appropriate
- know when referral to an HCM expert center is appropriate
This case study discussion is designed to be completed in 45 minutes.
- Screening family members for HCM, including genotype-positive phenotype-negative patients
- Genetic testing for HCM
- Continuity of care
At the end of this case study, delegates should be able to:
- Relate screening strategies for relatives of patients with HCM and apply to example data
- Explain the limitations associated with genetic screening for HCM
- Summarize appropriate clinical management strategies for genotype-positive phenotype-negative patients with HCM and apply these to sample patients
Accreditation for this course has expired. You may view the program, but CME/ CE is no longer available and no certificate will be issued.
Dr Anjali Tiku Owens, MD, Medical Director of the Advanced Heart Failure and Transplant Cardiology, Penn Center for Inherited Cardiovascular Disease / University of Pennsylvania, received financial compensation for consulting for MyoKardia / BMS and Cytokinetics.
Lisa Salberg, Founder and CEO of the Hypertrophic Cardiomyopathy Association (HCMA), has no relevant conflicts of interest to disclose.
Disclosure of educational planners:
Lauren Tebay, BA (mod), PhD, Senior Medical Writer, PCM Scientific, has no relevant conflicts of interest to disclose.
Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant conflicts of interest to disclose.
All relevant financial relationships have been mitigated.